299. Cystic fibrosis Clinical trials / Disease details


Clinical trials : 1,696 Drugs : 1,644 - (DrugBank : 272) / Drug target genes : 96 - Drug target pathways : 170

  
4 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT02163681
(ClinicalTrials.gov)
January 1, 201110/6/2014MRI as a Means to Measure Lung Function: Non-Invasive Imaging in Neonates and ChildrenHealthy;Cystic Fibrosis (CF);Asthma;Bronchopulmonary Dysplasia (BPD)Drug: Hyperpolarized Helium-3 MRI of the chestUniversity of VirginiaXemed LLCCompleted4 Months65 YearsAll77N/AUnited States
2NCT01161537
(ClinicalTrials.gov)
October 20109/7/2010Study of the Effect of VX-770 on Hyperpolarized Helium-3 Magnetic Resonance Imaging in Subjects With Cystic Fibrosis and the G551D MutationA Phase 2, Single-Blind, Placebo-Controlled Study to Evaluate the Effect of VX-770 on Hyperpolarized Helium-3 Magnetic Resonance Imaging in Subjects With Cystic Fibrosis, the G551D Mutation, and FEV1 =40% PredictedCystic FibrosisDrug: VX-770;Drug: PlaceboVertex Pharmaceuticals IncorporatedCystic Fibrosis Foundation TherapeuticsCompleted12 YearsN/AAll13Phase 2United States
3NCT00846573
(ClinicalTrials.gov)
November 200816/2/2009Hyperpolarized Noble Gas MR Imaging for Pulmonary DisordersHyperpolarized Noble Gas MR Imaging for Pulmonary DisordersCOPD;Cystic Fibrosis;Asthma;HealthyDrug: Hyperpolarized Helium-3University of Massachusetts, WorcesterNULLTerminated5 YearsN/AAll14N/AUnited States
4EUCTR2017-000672-28-Outside-EU/EEA
(EUCTR)
27/03/2017Study of the Effect of VX-770 on Hyperpolarized Helium-3 MagneticResonance Imaging in Subjects With Cystic Fibrosis and the G551DMutationA Phase 2, Single-Blind, Placebo-Controlled Study to Evaluate the Effectof VX-770 on Hyperpolarized Helium-3 Magnetic Resonance Imaging inSubjects With Cystic Fibrosis, the G551D Mutation, and FEV1 =40%Predicted cystic fibrosis
MedDRA version: 19.1;Level: SOC;Classification code 10010331;Term: Congenital, familial and genetic disorders;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16]
Trade Name: Kalydeco
Product Name: ivacaftor
Product Code: VX-770
INN or Proposed INN: IVACAFTOR
Vertex Pharmaceuticals IncorporatedNULLNAFemale: yes
Male: yes
17Phase 2United States